DBV Technologies announces its participation in two investor conferences in May

DBV Technologies, a company in the biopharmaceutical sector, has confirmed its presence through its Managing Director, Daniel Tassé, at two important investor conferences planned for May. These presentations will take place during the JMP Life Sciences Conference on May 13 at the Hilton Midtown Hotel in New York, and the HC Wainwright BioConnect Conference on May 20 at the NASDAQ World Headquarters, also in New York.

Interested parties will be able to follow the presentations live on the DBV Technologies website, and they will be available for rebroadcast for a period of 90 days after the events. These conferences mark a key milestone for DBV Technologies, which highlights its latest advances in the treatment of food allergies thanks to its Viaskin technology platform.